Combination chemotherapy with mitomycin C and cisplatin for advanced gastric cancer with multiple liver metastases

Yoshiro Saikawa, Tetsuro Kubota, Toshiharu Furukawa, Koichiro Kumai, Keiichi Yoshino, Kyuya Ishibiki, Masaki Kitajima

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A patient with advanced gastric cancer with multiple liver metastases was treated by reduction surgery at the primary site as well as by the intraarterial administration of mitomycin C (MMC) and cisplatin (CDDP) through a reservoir catheter inserted into the proper hepatic artery. After a palliative subtotal gastrectomy, MMC 8 mg/m2 was administered intraarterially (i.a.) followed by the administration of CDDP 80 or 40 mg/m2 i.a. with an interval of less than 1 week. After the completion of five courses of this regimen, a complete reduction of the hepatic tumors was achieved, while the level of serum carcinoembryonic antigen decreased to the normal range. The patient is currently alive with signs of disease recurrence at 17 months after initial diagnosis, while additional therapy with MMC + CDDP was continuously undergone until 17 months' after initial diagnosis with various interval. Although thrombocytopenia occurred during the treatment, it resolved within a few weeks after completing the combination chemotherapy without any specific treatment. The present case showed a better prognosis than we had expected, which suggested that combination chemotherapy with MMC and CDDP might thus be clinically useful because of its excellent antitumor activity and low toxicity.

Original languageEnglish
Pages (from-to)819-822
Number of pages4
JournalSurgery Today
Volume24
Issue number9
DOIs
Publication statusPublished - 1994 Sep

Fingerprint

Mitomycin
Combination Drug Therapy
Cisplatin
Stomach Neoplasms
Neoplasm Metastasis
Liver
Hepatic Artery
Carcinoembryonic Antigen
Gastrectomy
Thrombocytopenia
Reference Values
Therapeutics
Catheters
Recurrence
Serum
Neoplasms

Keywords

  • cisplatin
  • combination therapy
  • endocrine cell carcinoma
  • gastric cancer
  • liver metastasis
  • mitomycin C

ASJC Scopus subject areas

  • Surgery

Cite this

Combination chemotherapy with mitomycin C and cisplatin for advanced gastric cancer with multiple liver metastases. / Saikawa, Yoshiro; Kubota, Tetsuro; Furukawa, Toshiharu; Kumai, Koichiro; Yoshino, Keiichi; Ishibiki, Kyuya; Kitajima, Masaki.

In: Surgery Today, Vol. 24, No. 9, 09.1994, p. 819-822.

Research output: Contribution to journalArticle

Saikawa, Yoshiro ; Kubota, Tetsuro ; Furukawa, Toshiharu ; Kumai, Koichiro ; Yoshino, Keiichi ; Ishibiki, Kyuya ; Kitajima, Masaki. / Combination chemotherapy with mitomycin C and cisplatin for advanced gastric cancer with multiple liver metastases. In: Surgery Today. 1994 ; Vol. 24, No. 9. pp. 819-822.
@article{f4ca06d8ca6148a8802446c78b605581,
title = "Combination chemotherapy with mitomycin C and cisplatin for advanced gastric cancer with multiple liver metastases",
abstract = "A patient with advanced gastric cancer with multiple liver metastases was treated by reduction surgery at the primary site as well as by the intraarterial administration of mitomycin C (MMC) and cisplatin (CDDP) through a reservoir catheter inserted into the proper hepatic artery. After a palliative subtotal gastrectomy, MMC 8 mg/m2 was administered intraarterially (i.a.) followed by the administration of CDDP 80 or 40 mg/m2 i.a. with an interval of less than 1 week. After the completion of five courses of this regimen, a complete reduction of the hepatic tumors was achieved, while the level of serum carcinoembryonic antigen decreased to the normal range. The patient is currently alive with signs of disease recurrence at 17 months after initial diagnosis, while additional therapy with MMC + CDDP was continuously undergone until 17 months' after initial diagnosis with various interval. Although thrombocytopenia occurred during the treatment, it resolved within a few weeks after completing the combination chemotherapy without any specific treatment. The present case showed a better prognosis than we had expected, which suggested that combination chemotherapy with MMC and CDDP might thus be clinically useful because of its excellent antitumor activity and low toxicity.",
keywords = "cisplatin, combination therapy, endocrine cell carcinoma, gastric cancer, liver metastasis, mitomycin C",
author = "Yoshiro Saikawa and Tetsuro Kubota and Toshiharu Furukawa and Koichiro Kumai and Keiichi Yoshino and Kyuya Ishibiki and Masaki Kitajima",
year = "1994",
month = "9",
doi = "10.1007/BF01636313",
language = "English",
volume = "24",
pages = "819--822",
journal = "Surgery Today",
issn = "0941-1291",
publisher = "Springer Japan",
number = "9",

}

TY - JOUR

T1 - Combination chemotherapy with mitomycin C and cisplatin for advanced gastric cancer with multiple liver metastases

AU - Saikawa, Yoshiro

AU - Kubota, Tetsuro

AU - Furukawa, Toshiharu

AU - Kumai, Koichiro

AU - Yoshino, Keiichi

AU - Ishibiki, Kyuya

AU - Kitajima, Masaki

PY - 1994/9

Y1 - 1994/9

N2 - A patient with advanced gastric cancer with multiple liver metastases was treated by reduction surgery at the primary site as well as by the intraarterial administration of mitomycin C (MMC) and cisplatin (CDDP) through a reservoir catheter inserted into the proper hepatic artery. After a palliative subtotal gastrectomy, MMC 8 mg/m2 was administered intraarterially (i.a.) followed by the administration of CDDP 80 or 40 mg/m2 i.a. with an interval of less than 1 week. After the completion of five courses of this regimen, a complete reduction of the hepatic tumors was achieved, while the level of serum carcinoembryonic antigen decreased to the normal range. The patient is currently alive with signs of disease recurrence at 17 months after initial diagnosis, while additional therapy with MMC + CDDP was continuously undergone until 17 months' after initial diagnosis with various interval. Although thrombocytopenia occurred during the treatment, it resolved within a few weeks after completing the combination chemotherapy without any specific treatment. The present case showed a better prognosis than we had expected, which suggested that combination chemotherapy with MMC and CDDP might thus be clinically useful because of its excellent antitumor activity and low toxicity.

AB - A patient with advanced gastric cancer with multiple liver metastases was treated by reduction surgery at the primary site as well as by the intraarterial administration of mitomycin C (MMC) and cisplatin (CDDP) through a reservoir catheter inserted into the proper hepatic artery. After a palliative subtotal gastrectomy, MMC 8 mg/m2 was administered intraarterially (i.a.) followed by the administration of CDDP 80 or 40 mg/m2 i.a. with an interval of less than 1 week. After the completion of five courses of this regimen, a complete reduction of the hepatic tumors was achieved, while the level of serum carcinoembryonic antigen decreased to the normal range. The patient is currently alive with signs of disease recurrence at 17 months after initial diagnosis, while additional therapy with MMC + CDDP was continuously undergone until 17 months' after initial diagnosis with various interval. Although thrombocytopenia occurred during the treatment, it resolved within a few weeks after completing the combination chemotherapy without any specific treatment. The present case showed a better prognosis than we had expected, which suggested that combination chemotherapy with MMC and CDDP might thus be clinically useful because of its excellent antitumor activity and low toxicity.

KW - cisplatin

KW - combination therapy

KW - endocrine cell carcinoma

KW - gastric cancer

KW - liver metastasis

KW - mitomycin C

UR - http://www.scopus.com/inward/record.url?scp=0028081807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028081807&partnerID=8YFLogxK

U2 - 10.1007/BF01636313

DO - 10.1007/BF01636313

M3 - Article

C2 - 7532479

AN - SCOPUS:0028081807

VL - 24

SP - 819

EP - 822

JO - Surgery Today

JF - Surgery Today

SN - 0941-1291

IS - 9

ER -